Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 ...
Gaithersburg: Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M adjuvant, has announced that ...
Oxford University Innovation (OUI), the technology transfer office of the University of Oxford, has launched its 2024 report ...
The seasonal flu places a significant burden on healthcare systems globally, leading to over five million hospitalizations ...
Increased capabilities for genomic surveillance have offered new insights into global viral evolution. Seasonal flu showed a 'remarkable' bounce back to pre-pandemic levels once international air ...
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M adjuvant, today ...
and the Imperial College London and Oxford Population Health. A study has highlighted ways to reduce RSV infections - ...
Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...
The past 12 months have also seen the first deliveries of Oxford’s R21/Matrix-M malaria vaccine in Africa, following a ...
Infinitopes, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, today announ ...
Seasonal influenza epidemics impose substantial burdens on healthcare systems and cause >5 million hospitalizations of adults each year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback